Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein-1 release and structural remodelling of the lung in human and rodent chronic heart failure models

Thorax

Volumn 69, Issue 12, 2014, Pages 1120-1127

  Park, John E S ^a   Lyon, Alexander R ^a,b   Shao, Dongmin ^a,b   Hector, Lauren R ^a   Xu, Hua ^b   O'Gara, Peter ^a   Pinhu, Liao ^a   Chambers, Rachel C ^c   Wort, S John ^a,b   Griffiths, Mark J D ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; INTERLEUKIN 6; LUNG COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG; ATP2A2 PROTEIN, RAT; CCL2 PROTEIN, HUMAN; CULTURE MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME PHOSPHORYLATION; FETUS; GENE EXPRESSION REGULATION; GENE THERAPY; HEART FAILURE; HEART INFARCTION; HEART WEIGHT; HUMAN; HUMAN CELL; IL 6 GENE; IN VITRO STUDY; LUNG DISEASE; LUNG STRUCTURAL REMODELLING; MALE; MCP 1 GENE; MECHANICAL STRESS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; AIRWAY REMODELING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; COMPLICATION; CULTURE MEDIUM; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; FIBROBLAST; GENETICS; HYPERTENSION, PULMONARY; MECHANOTRANSDUCTION; METABOLISM; PATHOPHYSIOLOGY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

AIRWAY REMODELING; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; GENE EXPRESSION REGULATION; GENETIC THERAPY; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; MAP KINASE SIGNALING SYSTEM; MECHANOTRANSDUCTION, CELLULAR; MYOCARDIAL INFARCTION; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; STRESS, MECHANICAL; UP-REGULATION;

EID: 84919815886     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-204190     Document Type: Article

References (45)

1. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999;20:421-8.
2. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-57.
3. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-76.
4. Mettauer B, Lampert E, Charloux A, et al. Lung membrane diffusing capacity, heart failure, and heart transplantation. Am J Cardiol 1999;83:62-7.
5. Naum CC, Sciurba FC, Rogers RM. Pulmonary function abnormalities in chronic severe cardiomyopathy preceding cardiac transplantation. Am Rev Respir Dis 1992;145:1334-8.
6. Agostoni PG, Guazzi M, Bussotti M, et al. Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. J Am Coll Cardiol 2000;36:1600-4.
7. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004;125:669-82.
8. Huang W, Kingsbury MP, Turner MA, et al. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 2001;49:207-17.
9. Jasmin JF, Calderone A, Leung TK, et al. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res 2003;58:621-31.
10. Kingsbury MP, Huang W, Donnelly JL, et al. Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol 2003;98:295-303.
11. Abdalla SA, Gallione CJ, Barst RJ, et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004;23:373-7.
12. Aukrust P, Damas JK, Gullestad L, et al. Chemokines in myocardial failure - pathogenic importance and potential therapeutic targets. Clin Exp Immunol 2001;124:343-5.
13. Aukrust P, Yndestad A, Damas JK, et al. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. Autoimmun Rev 2004;3:221-7.
14. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
15. Damas JK, Eiken HG, Oie E, et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000;47:778-87.
16. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005;95 (11A):17C-23C; discussion 38C-40C.
17. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
18. Gaertner R, Lepailleur-Enouf D, Gonzalez W, et al. Pulmonary endothelium as a site of synthesis and storage of interleukin-6 in experimental congestive heart failure. Eur J Heart Fail 2003;5:435-42.
19. Haseneen NA, Vaday GG, Zucker S, et al. Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN. Am J Physiol Lung Cell Mol Physiol 2003;284:L541-7.
20. Cheng JJ, Wung BS, Chao YJ, et al. Cyclic strain-induced reactive oxygen species involved in ICAM-1 gene induction in endothelial cells. Hypertension 1998;31:125-30.
21. Wung BS, Cheng JJ, Hsieh HJ, et al. Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1. Circ Res 1997;81:1-7.
22. Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med 2008;5:554-65.
23. Lipskaia L, Ly H, Kawase Y, et al. Treatment of heart failure by calcium cycling gene therapy. Future Cardiol 2007;3:413-23.
24. del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001;104:1424-9.
25. Lyon AR, Bannister ML, Collins T, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol 2011;4:362-72.
26. Sakata S, Lebeche D, Sakata N, et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 2007;42:852-61.
27. Pinhu L, Park JE, Yao W, et al. Reference gene selection for real-time polymerase chain reaction in human lung cells subjected to cyclic mechanical strain. Respirology 2008;13:990-9.
28. Lyon AR, MacLeod KT, Zhang Y, et al. Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proc Natl Acad Sci USA 2009;106:6854-9.
29. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005;166:1353-65.
30. Dixon DL, De Pasquale CG, De Smet HR, et al. Reduced surface tension normalizes static lung mechanics in a rodent chronic heart failure model. Am J Respir Crit Care Med 2009;180:181-7.
31. Wung BS, Cheng JJ, Shyue SK, et al. NO modulates monocyte chemotactic protein-1 expression in endothelial cells under cyclic strain. Arterioscler Thromb Vasc Biol 2001;21:1941-7.
32. Antoniades HN, Neville-Golden J, Galanopoulos T, et al. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 1992;89:5371-5.
33. Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011;13:1087-95.
34. Sun L, Louie MC, Vannella KM, et al. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol 2011;300:L341-53.
35. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-84.
36. Moore BB, Peters-Golden M, Christensen PJ, et al. Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol 2003;284:L342-9.
37. Bachofen H, Schurch S, Urbinelli M, et al. Relations among alveolar surface tension, surface area, volume, and recoil pressure. J Appl Physiol 1987;62:1878-87.
38. Byrne MJ, Power JM, Preovolos A, et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008;15:1550-7.
39. Lompre AM, Anger M, Levitsky D. Sarco(endo)plasmic reticulum calcium pumps in the cardiovascular system: function and gene expression. J Mol Cell Cardiol 1994;26:1109-21.
40. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008;14:355-67.
41. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-13.
42. El-Chemaly S, Malide D, Zudaire E, et al. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci USA 2009;106:3958-63.
43. Jiang BH, Tardif JC, Shi Y, et al. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J 2011;37:578-86.
44. Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-19.
45. Ikeda Y, Yonemitsu Y, Kataoka C, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002;283:H2021-8.